{"slideshow_credits": null, "snippet": "The drug maker\u2019s offer for Synageva has a huge 136 percent premium. Still, exchanging a chunk of high-priced paper for assets may be a savvy move.", "abstract": null, "section_name": "Business Day", "print_page": null, "document_type": "article", "byline": {"person": [{"firstname": "Robert", "role": "reported", "lastname": "CYRAN", "rank": 1, "organization": ""}], "original": "By ROBERT CYRAN"}, "web_url": "http://www.nytimes.com/2015/05/07/business/dealbook/alexion-puts-its-soaring-stock-price-to-good-use.html", "lead_paragraph": "The drug maker\u2019s offer for Synageva has a huge 136 percent premium. Still, exchanging a chunk of high-priced paper for assets may be a savvy move.", "headline": {"main": "Alexion Puts Its Soaring Stock Price to Good Use", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "_id": "554ab8da38f0d85a643468ce", "word_count": "384", "multimedia": [], "pub_date": "2015-05-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "2"}, {"name": "organizations", "value": "Alexion Pharmaceuticals Inc", "is_major": "N", "rank": "3"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}